Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05883748




Registration number
NCT05883748
Ethics application status
Date submitted
22/05/2023
Date registered
1/06/2023
Date last updated
22/02/2024

Titles & IDs
Public title
Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP
Scientific title
An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With Erythropoietic Protoporphyria (EPP)
Secondary ID [1] 0 0
DISC-1459-501
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Erythropoietic Protoporphyria 0 0
Condition category
Condition code
Skin 0 0 0 0
Other skin conditions
Blood 0 0 0 0
Other blood disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - DISC-1459
Treatment: Drugs - DISC-1459

Experimental: DISC-1459 Oral Dose Level 1 - Oral dose, once a day

Experimental: DISC-1459 Oral Dose Level 2 - Oral dose, once a day


Treatment: Drugs: DISC-1459
DISC-1459 dose level 1

Treatment: Drugs: DISC-1459
DISC-1459 dose level 2
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of treatment-emergent adverse events
Timepoint [1] 0 0
up to 5 Years
Primary outcome [2] 0 0
Incidence of clinically abnormal vital signs
Timepoint [2] 0 0
up to 5 Years
Primary outcome [3] 0 0
Incidence of clinically abnormal physical exam
Timepoint [3] 0 0
up to 5 Years
Primary outcome [4] 0 0
Incidence of abnormal laboratory test results
Timepoint [4] 0 0
up to 5 Years
Primary outcome [5] 0 0
Assessment of Patient Health Questionnaire (PHQ-8)
Timepoint [5] 0 0
up to 5 Years
Primary outcome [6] 0 0
Assessment of C-SSRS
Timepoint [6] 0 0
up to 5 Years
Secondary outcome [1] 0 0
Change from baseline in daily daylight tolerance, as assessed by total hours spent in the sunlight without pain and average time to first prodromal syndrome in sunlight
Timepoint [1] 0 0
up to 5 Years
Secondary outcome [2] 0 0
Change from baseline in whole blood metal-free PPIX levels
Timepoint [2] 0 0
up to 5 Years
Secondary outcome [3] 0 0
Plasma Bitopertin Concentrations
Timepoint [3] 0 0
up to 5 Years

Eligibility
Key inclusion criteria
- Participants with diagnosis of EPP who are participating (or who have participated) in
a prior Disc Medicine bitopertin study and who have completed the randomized treatment
phase and End-of-Study visit

- Aged =12 years upon study consent

- Body weight =32 kg for participants <18 years of age and BMI =18.5 kg/m2 for adult
participants
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participants who have an ongoing SAE from a clinical study that is assessed by the
investigator as related to bitopertin

- Other medical or psychiatric condition or laboratory finding not specifically noted
above that, in the judgement of the Investigator or Sponsor, would put the participant
at unacceptable risk or otherwise preclude participation in the study

- Condition or concomitant medication that would confound the ability to interpret
clinical, clinical laboratory, or participant diary data, including a major
psychiatric condition that has had an exacerbation or required hospitalization in the
last 6 months

- Planned treatment with afamelanotide or dersimelagon during the study

- Planned use of any drugs or herbal remedies known to be strong inhibitors or inducers
of cytochrome p450 (CYP)3A4 enzymes throughout the study

- If female, pregnant, or breastfeeding

- Participation in any other clinical protocol or investigational trial, other than Disc
Medicine bitopertin trials, that involves administration of experimental therapy
and/or therapeutic devices within 30 days of Day 1

- Score of PHQ-8 =10 at screening or any response of "yes" on the C-SSRS

- Grapefruit/Seville orange and products containing these for 14 days prior to first
dose of study drug and throughout the stud

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2/Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
31/08/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2028
Actual
Sample size
Target
200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Washington

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Disc Medicine, Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is an open-label, long-term extension study to investigate the safety, tolerability and
efficacy of DISC-1459 in participants with EPP.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05883748
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Will Savage, MD PhD
Address 0 0
Disc Medicine
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05883748